Novocure(NVCR.US)

Last Updated 19:00:00 ET
longbridge loading

NovoCure (NVCR) Is Up 9.7% After Raising 2026 Revenue Outlook And Posting Stronger Q1 Sales

Simplywall·
US
NVCR
+0.85%
US
BIB
+1.41%
US
FBT
+0.69%
Simplywall·
US
NVCR
+0.85%
US
BIB
+1.41%
US
FBT
+0.69%

3 Overlooked Stocks Set to Soar in 2026

nasdaq·
US
MBX
+1.15%
US
NVCR
+0.85%
US
AXSM
+1.31%
nasdaq·
US
MBX
+1.15%
US
NVCR
+0.85%
US
AXSM
+1.31%

Stocks with rising relative price strength: Novocure

MSN·
US
NVCR
+0.85%
US
SBIO
+1.84%
US
LABU
+2.48%
MSN·
US
NVCR
+0.85%
US
SBIO
+1.84%
US
LABU
+2.48%

NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook

Simplywall·
US
NVCR
+0.85%
US
XBI
+0.81%
US
LABU
+2.48%
Simplywall·
US
NVCR
+0.85%
US
XBI
+0.81%
US
LABU
+2.48%

NovoCure shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY26 sales guidance with its midpoint above estimates.

benzinga_article·
US
NVCR
+0.85%
US
XHE
+0.20%
US
IHI
-0.71%
benzinga_article·
US
NVCR
+0.85%
US
XHE
+0.20%
US
IHI
-0.71%

NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript

benzinga_article·
US
NVCR
+0.85%
benzinga_article·
US
NVCR
+0.85%

Novocure | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 174.06 M

Earnings Watch·
US
NVCR
+0.85%
Earnings Watch·
US
NVCR
+0.85%

NovoCure Q1 2026 earnings preview

MSN·
US
NVCR
+0.85%
US
BIB
+1.41%
US
FBT
+0.69%
MSN·
US
NVCR
+0.85%
US
BIB
+1.41%
US
FBT
+0.69%
© 2026 Longbridge｜Disclaimer